Redbiotec AG, a pioneer in living medicines, further expands its Scientific Advisory Board with the appointment of Professor Michele Calos, PhD. Dr. Calos is a Professor of Genetics at Stanford University. A recent President of the American Society of Gene and Cell Therapy (ASGCT), Dr. Calos brings over four decades of research experience in genetics and genomic modification and has been focused on developing novel gene and cell therapies to improve the clinical condition of patients suffering from genetic disorders like muscular dystrophy. Dr. Calos has also served on the Advisory Committee to the FDA with regard to cell, tissue and gene therapies. Dr. Calos is an Oxford graduate and received her PhD in Biochemistry & Molecular Biology from Harvard University.
As Redbiotec enters the field of gene therapy with engineered bacteria as means to improve in vivo delivery of therapeutics, we greatly appreciate the research experience and regulatory insights brought by Dr. Calos.